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Introduction
Heart failure with reduced ejection fraction (HFrEF) is a
cardiovascular disease distinguished by low-grade chronic
inflammation1. Literature suggests that disturbed metabolic
pathways within cardiomyocyte mitochondria play a
significant role in systemic wide inflammation seen in
HFrEF2. These mechanisms are linked to the activation of
cytokine receptor Interleukin-1 (IL-1). This has led to the
testing of repurposed drug therapies such as Kineret
(Anakinra) that inhibits the activation of IL-1. To measure the
outcomes of Anakinra, investigators have used
cardiopulmonary exercise tests (CPET) and high-sensitivity
CRP (hs-CRP)3,4. Clinical trials using these markers have
demonstrated promise for reducing inflammation after 12
weeks of administration5. Little is known though as to how
Anakinra impacts the heart’s metabolic pathways underlying
inflammation. Therefore we have taken a hypothesis-driven
approach to characterize the HFrEF metabolic pathways
affected by Anakinra for different therapeutic durations; for
durations of 2 weeks (Ank-2) and for 12 weeks (Ank-12).
Methods
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Results
Metabolites and lipids revealed inflammatory and energetic
pathways responding to Ank-12. The TCA cycle and butanoate
metabolism were among those reported. Downstream IL-1,
inflammatory hsCRP was expected to decrease. After Ank-12
hsCRP levels markedly decreased indicating reduced systemic
inflammation. Medium and long-chain acylcarnitines (Acyl) C10:0
and C16:0 are elevated due to oxidative stress, an imbalance
that leads to inflammation. It was hypothesized concentrations of
Acyl would decrease after Ank-12; due to decreasing
inflammation and restoring cardiac function re-enabling cardiac
mitochondrial FA β-oxidation (FAO). Healthy hearts rely on FAO
for ~95% of ATP production. During HFrEF there is a shift
towards utilizing glucose and ketones6. Overall glucose
metabolism also improved with treatment indicated by decrease
in hexose in response to treatment. For ketone bodies, 3-
hydroxybutyric acid (BHA) is consumed by failing hearts. Higher
levels of BHA following Ank-12 implies less consumption of and
reliance on BHA. This study provides the metabolomic logic
behind Ank-12’s response for patients.
Post-hoc analysis was performed on 49 patients with
reduced ejection fraction, mostly African American (79.6%) and
male (75.5%) from the VCU REDHART study. Lipids from
HFrEF patients’ plasma and serum were quantified via a ScieX
TripleTOF 6600 mass spectrometry paired to an Agilent 1290
liquid chromatograph (LC). An acquity UPLC CSH C18 column
(100 x 2.1 mm; 1.7µm) was used with the LC. Metabolites were
acquired by a Leco Pegasus IV TOF mass spectrometer
coupled to an Agilent 6890 gas chromatograph (GC) equipped
with a Gerstel automatic liner exchange system (ALEX) that
included a multipurpose sample (MPS2) dual rail, and a Gerstel
CIS cold injection system. Metabolic data were filtered to
exclude detected exogenous metabolites identified as
medications or products of gut microbiota. Data were
normalized, filtered using IQR, log transformed, and pareto
scaled. Regularized Linear Discriminant Analysis (rLDA) was
used to discover any meaningful group separations based on
acquired metabolites and lipids. Metabolic Pathway Analysis
selected enriched metabolites that had been annotated on Kyoto
Encyclopedia of Genes and Genomes (KEGG). A multivariate
analysis generated a biologically valid testable hypothesis on the
direction of analytes in response to Anakinra. A final univariate
metabolomic analysis revealed that the circulating metabolic
profiles of patients treated with Anakinra compared to placebo
were significantly different after 12 weeks of treatment (one-
tailed t-test, p<0.05). All analyses were performed in
Metaboanalyst 4.0 and JMP 14 Pro.
Limitations and Future Directions
Figure 1: Baseline and treatment groups’ separation
obtained from analytes. Regularized Linear Discriminant
Analysis (r-LDA) demonstrated group separation after stepwise
selection of 30 lipids and metabolites. Selected predictors
explain the group’s differences and spatial separation.
Mahalanobis distance from baseline revealed that Anakinra 2
weeks and Anakinra 12 weeks treatment can be distinguished
from Placebo (Entropy R2= 0.99 – 0% misclassification).
Figure 2: Metabolic pathways associated with Anakinra
treatment. Ellipse diameter indicated the magnitude of the
impact on the pathway enrichment analysis. All pathways had a
statistically significant impact in the enrichment analysis
(p<0.05). Ellipse color represent p-value (yellow= low, red=high).
Only metabolic pathways with p-value p≤ 0.5 are labeled.
Figure 3: Comparison of significant CRP and acylcarnitine
modulations from baseline and treatment groups. Treatment
groups were Anakinra 2 weeks, Anakinra 12 weeks and placebo
12 weeks. All values (y-axis) are normalized. Analysis of
variance (ANOVA) retrieved p≤0.05 per analyte.
Figure 4: Anakinra 12-weeks yields benefits compared to
placebo. The derived hypothesis that Anakinra after 12 weeks
would carry a different effect on the metabolome compared to
placebo, tested with one-tailed t-test. All values (y-axis) are
normalized. Metabolites statistically different (p≤0.05) suggested
metabolic changes following 12 weeks of Anakinra treatment.
Table 1: Metabolomic functions affected by Anakinra
following 12-weeks treatment. Hypothesis-driven test of
Anakinra effect different from placebo after 12 weeks (one-tailed
Student’s t-test). The hypothesis tested the downregulation of
inflammatory markers, and upregulation of metabolites and
pathways participating in cardiac energy production. Effects are
represented by color (green = low, red= high).
Pathway Impact
-lo
g(
p)
⬤ Baseline  ⬤ Placebo  ⬤ Anakinra 2-wks  ⬤ Anakinra 12-wks
⬤ Placebo  ⬤ Anakinra 12-wks
CRP Acylcarnitine C10:0 Acylcarnitine C16:0
3-hydroxybutyric acid Hexose
CRP Acylcarnitine C10:0
Acylcarnitine C16:0
⬤ Baseline ⬤ Placebo  ⬤ Anakinra 2-wks  ⬤ Anakinra 12-wks
Small sample size may have skewed the results of Anakinra
effect towards representing an African American male subgroup.
Baseline metabolic variability highly affected the power of the
analysis in detecting metabolites post-treatment. Variability was
overcome by a Random Forest outlier detection algorithm to
select baseline values that did not significantly differ from the
treatment groups. Nonetheless, meaningful changes resultant of
IL-1 blockade were detected after 12 weeks of treatment. Future
studies applying metabolomic techniques with more power could
show Anakinra alterations earlier than 12 weeks.
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